Leonard S. Schleifer - Nov 19, 2021 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role
President & CEO, Director
Signature
/s/**Leonard S. Schleifer
Stock symbol
REGN
Transactions as of
Nov 19, 2021
Transactions value $
-$119,112,839
Form type
4
Date filed
11/19/2021, 04:50 PM
Previous filing
Aug 20, 2021
Next filing
Apr 4, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock Options Exercise $64.6M +239K +78.45% $270.43 544K Nov 19, 2021 Direct
transaction REGN Common Stock Tax liability -$113M -173K -31.9% $651.96 370K Nov 19, 2021 Direct
transaction REGN Common Stock Options Exercise $50.4M +281K +75.95% $179.13 652K Nov 19, 2021 Direct
transaction REGN Common Stock Tax liability -$121M -186K -28.49% $651.96 466K Nov 19, 2021 Direct
holding REGN Common Stock 200K Nov 19, 2021 2021 GRAT
holding REGN Common Stock 5.87K Nov 19, 2021 By 401(k) Plan
holding REGN Common Stock 21.2K Nov 19, 2021 By Trust F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction REGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -281K -100% $0.00* 0 Nov 19, 2021 Common Stock 281K $179.13 Direct F2
transaction REGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -239K -100% $0.00* 0 Nov 19, 2021 Common Stock 239K $270.43 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares are held in a trust for the benefit of the reporting person's family members. The reporting person's spouse is a trustee of the trust.
F2 The stock option award vests in four equal annual installments, commencing one year after the date of grant.